In vitro circadian ANP secretion by gene transferring cells encapsulated in polycaprolactone tubes: gene chronotherapy.
A new insofar as chronobiologic therapeutic approach by atrial natriuretic peptide (ANP) for hypertension and/or congestive heart failure (CHF) is based on the release of ANP from ANP cDNA transfected Chinese Hamster Ovary (CHO) cells encapsulated in polycaprolactone (PCL) tubes. ANP secretion was maintained for at least 6 months. The encapsulated cells remained viable during culturing. Control cells without transferred ANP cDNA were negative. ANP secretion is circadian periodic, peaking around 04:18, shifted to around 07:56 by melatonin treatment. The encapsulation technique, based on principles of chronotherapy, may provide a more efficient gene therapy, applicable for eventual human implantation of gene transferred cells.
Wang
Zhengrong
Z
West China Medical Center, Sichuan University, Chengdu, Sichuan 610041, PR China.
Chen
Liguo
L
Wan
Chaomin
C
Qu
Yi
Y
Cornélissen
G
G
Halberg
F
F
D000818:Animals; D009320:Atrial Natriuretic Factor / Q000235:genetics / Q000378:metabolism* / Q000627:therapeutic use*; D016466:CHO Cells; D019454:Chronotherapy / Q000379:methods*; D002940:Circadian Rhythm / Q000187:drug effects / Q000502:physiology*; D006224:Cricetinae; D016503:Drug Delivery Systems; D005455:Fluorescent Antibody Technique; D006333:Heart Failure / Q000188:drug therapy; D006801:Humans; D020007:Implants, Experimental; D011091:Polyesters / Q000737:chemistry*; D013499:Surface Properties; D013997:Time Factors; D014162:Transfection
D011091:Polyesters; C016240:polycaprolactone; D009320:Atrial Natriuretic Factor